Clinical Trial: A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quies
Brief Summary: The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
Detailed Summary:
Sponsor: Lux Biosciences, Inc.
Current Primary Outcome: recurrence of ocular inflammation [ Time Frame: 26 weeks ]
Original Primary Outcome:
Current Secondary Outcome:
- BCVA [ Time Frame: 26 weeks ]
- systemic corticosteroid usage [ Time Frame: 26 weeks ]
Original Secondary Outcome:
Information By: Lux Biosciences, Inc.
Dates:
Date Received: November 27, 2006
Date Started: January 2007
Date Completion:
Last Updated: June 21, 2012
Last Verified: June 2012
